MDM2 is an E3 ligase that promotes ubiquitin-mediated destruction of p53. Cellular stresses such as DNA damage can lead to p53 activation due in part to MDM2 destabilization. Here, we show that the stability of MDM2 is regulated by an ubiquitin-like NEDD8 pathway and identify NEDP1 as a chemotherapy-induced isopeptidase that deneddylates MDM2, resulting in MDM2 destabilization concomitant with p53 activation. Concordantly, RNAi-mediated knockdown of endogenous NEDP1 blocked diminution of MDM2 levels and increased chemoresistance of tumor cells. These findings unveil the regulation of MDM2 stability through NEDP1 as a common molecular determinant governing chemotherapy-induced p53-dependent cell death.
Introduction
Deregulation of the p53 pathway is observed in most human tumors. Approximately 50% of tumors harbor inactivating mutations in the p53 gene, whereas the remaining tumors show suppressed, albeit wild-type p53 activity owing to a variety of mechanisms including overexpression of MDM2, which represents an alternative and direct mechanism of p53 inactivation (Toledo and Wahl, 2006) . MDM2 is also a critical regulator of p53 during development, shown by the embryonic lethality phenotype of MDM2-null mice that is rescued by concomitant loss of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995) . In addition, an E3 ligasedefective MDM2 mutant was unable to rescue MDM2-null mice phenotype (Itahana et al., 2007) . These observations establish the biological importance of MDM2 E3 activity in the negative regulation of p53.
In response to DNA damage, p53 becomes phosphorylated by several kinases within the MDM2-binding domain, which prevents MDM2-p53 interaction (Bode and Dong, 2004 ). The stabilization of p53 then leads to DNA repair, cell cycle arrest, senescence or apoptosis. Recent studies have shown that MDM2 is destabilized in response to DNA damage, which promotes p53 activation (Stommel and Wahl, 2004; Meulmeester et al., 2005) . NEDD8 is a ubiquitin-like protein that regulates protein function through covalent modification of substrates such as Cullins, BCA3, EGFR, ribosomal L11 protein, VHL, p73 and p53 (Xirodimas, 2008) . For example, NEDD8 modification of Cullins not only regulates the enzymatic activity of Cullin-based E3 ubiquitin ligases (Pan et al., 2004) , but also influences Cullin protein stability (Morimoto et al., 2003; Wu et al., 2005) . Neddylation of p53 mediated by MDM2 was shown to inhibit p53-transcriptional activity . Recent evidence suggests that MDM2 itself is subjected to NEDD8 modification. However, the molecular mechanisms governing MDM2 neddylation and its biological significance remain unclear.
Here, we examined the role of NEDD8 pathway in the regulation of MDM2. We identify for the first time a biological stimulus that affects the expression of a NEDD8-specific isopeptidase NEDP1, and show that modulation of NEDP1 upon various DNA-damaging chemotherapeutic drugs regulates p53 activity through regulation of MDM2 protein stability. Furthermore, RNAi-mediated suppression of NEDP1 increased MDM2 levels and chemoresistance of tumor cells. These findings uncover a novel role of NEDP1 in p53 activation in response to chemotherapy.
Results and discussion

Neddylation stabilizes MDM2
Ectopic expression of T7-NEDD8, but not T7-NEDD8DGG mutant that lacks the essential C-terminal glycine-glycine motif required for covalent conjugation of substrates, promoted significant MDM2 neddylation (Figure 1a) . Although this observation is consistent with a previous report showing MDM2 as a substrate of NEDD8 modification , we noted a dramatic dose-dependent increase in MDM2 levels with increasing amounts of T7-NEDD8 (Figure 1b) , Figure 1 Neddylation of MDM2 increases its protein stability. (a) HEK293 cells transfected with plasmids encoding human MDM2, T7-NEDD8 or conjugation-defective T7-NEDD8DGG, were lysed under denaturing conditions, resolved by SDS-PAGE and immunoblotted with the indicated antibodies (left panel) as previously described (Watson et al., 2006) . Cells transfected with empty plasmids (MOCK) or plasmids encoding T7-NEDD8 or T7-NEDD8DGG were lysed, equal amounts of whole cell extracts resolved by SDS-PAGE and immunoblotted with an anti-T7 antibody to validate the conjugation capability of the wild-type T7-NEDD8 versus T7-NEDD8DGG (right panel). (b) Cells were transfected with plasmids encoding MDM2 (left panel) or human HA-MDMX (right panel) (kindly provided by Dr Aart Jochemsen) with increasing amounts of T7-NEDD8 or T7-NEDDDGG. Cells were lysed under denaturing conditions, equal amounts of whole cell extracts resolved by SDS-PAGE and immunoblotted with either anti-MDM2 or anti-MDMX antibodies. (c) Cells transfected with plasmids encoding MDM2 with increasing amounts of His-Ubc12 or dominantnegative Ubc12(C111S) (DN-Ubc12) (kindly provided by Dr Edward Yeh) were lysed, resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (d) Cells were transfected with empty plasmids (MOCK) or plasmids encoding T7-NEDD8 or T7-NEDD8DGG. Forty-eight hours post-transfection, cells were treated with 40 mg/ml cycloheximide (CHX) (Sigma, St Louis, MO, USA) for the indicated time periods, lysed, equal amounts of lysates resolved by SDS-PAGE and immunoblotted with the indicated antibodies (left panel). Protein levels of endogenous MDM2 were quantified by densitometry using Image J (http://rsb.info.nih.gov/ij) software and plotted as a percentage of the no treatment baseline. A trendline was derived to determine the half-life of MDM2 (right panel) as previously described (Lau et al., 2007) Figure 1b ). However, MDM2(C464A) RING finger mutant that lacks E3 ligase activity was modified, albeit to a lesser extent, by NEDD8 and its expression level was increased by ectopic expression of NEDD8 (Supplementary Figure 1) . Therefore, we asked whether the known NEDD8 E2-conjugating enzyme Ubc12 modulates MDM2 levels. HEK293A cells transfected with increasing amounts of His-Ubc12 showed a dose-dependent increase in MDM2 ( Figure 1c , left panels). However, cells expressing increasing amounts of the dominantnegative Ubc12(C111S), which forms a stable interaction with NEDD8 ( Figure 1c , bottom right panel) and therefore has limited ability to transfer NEDD8 to target substrates, showed a striking dose-dependent decrease in MDM2 ( Figure 1c , right panels). We next asked whether the observed changes in MDM2 expression levels were because of alterations in MDM2 protein stability. Endogenous MDM2 half-life was approximately 30-40 min in cells expressing T7-NEDD8DGG mutant or an empty plasmid ( Figure 1d ). In contrast, cells ectopically expressing T7-NEDD8 showed a near threefold increase in MDM2 half-life to 1.6 h ( Figure 1d ). Similar results were observed in U2OS osteosarcoma cell line (Supplementary Figure 2) . Notably, only a minor fraction of MDM2 was observed to be neddylated at a given time (see Figure 1a ). However, conjugation and de-conjugation of ubiquitin and ubiquitin-like proteins such as NEDD8 and SUMO is a dynamic process and hence, a greater proportion of MDM2 is likely subjected to NEDD8 modification. In support of this notion, recent studies have shown that mutants lacking the NEDP1 homologs in S. Pombe and Drosophila significantly increased the profile of neddylated proteins that otherwise would not have been detected (Zhou and Watts, 2005; Chan et al., 2008) . These results suggest that NEDD8 conjugation promotes MDM2 protein stabilization.
NEDP1-mediated deneddylation promotes MDM2 destabilization
A corollary prediction is that deneddylation would lead to MDM2 destabilization. The two most commonly studied NEDD8-specific proteases are the COP9 signalosome complex, in which CSN5/JAB1 possesses the protease activity and the more recently identified NEDP1 Mendoza et al., 2003; Wu et al., 2003) . The importance of COP9 signalosome-dependent regulation of Cullin family members is well established. CSN5 was recently shown to stabilize MDM2 by inhibiting its autoubiquitylation function (Zhang et al., 2008) , which suggests that CSN5 is an unlikely candidate to promote MDM2 deneddylation. NEDP1 can also deneddylate Cullins in vitro, but NEDP1 shows three orders of magnitude less activity in cleaving neddylated Cul1 than COP9 signalosome (Yamoah et al., 2005) . Consistent with this observation, deletion of NEDP1 homologs in S. Pombe and Drosophila did not result in accumulation of neddylated Cul1 or Cul3 (Zhou and Watts, 2005; Chan et al., 2008) . However, a significant accumulation of as yet to-beidentified neddylated substrates was noted in both model systems upon deletion of NEDP1 homologs. Thus, we asked whether NEDP1 had a role in MDM2 deneddylation. Ectopic expression of myc-NEDP1, but not HA-CSN5, markedly attenuated the levels of neddylated MDM2 in a dose-dependent manner under conditions that favored robust MDM2 neddylation (Figure 2a) . Furthermore, cysteine protease activity of NEDP1 is required for MDM2 deneddylation as the catalytically defective myc-NEDP1(C163A) mutant failed to deneddylate MDM2 (Figure 2b) . Importantly, expression of NEDP1 decreased MDM2 levels while an ubiquitin-specific isopeptidase HAUSP increased MDM2 levels (Figure 2c ). Moreover, ectopic expression of myc-NEDP1 appeared to accelerate the turnover of endogenous MDM2 in contrast to the myc-NEDP1(-C163A) mutant (Figure 2d ). These results show that deneddylation destabilizes MDM2.
Chemotherapy increases NEDP1 levels MDM2 destabilization in response to DNA-damaging agents has been shown to have a critical role in p53 activation (Toledo and Wahl, 2006) . Recently, the activity of COP9 signalosome deneddylating complex was shown to increase in response to apoptotic stimuli whereas ubiquitin E2 enzyme Ubc5b/c protein levels were shown to decrease in response to doxorubicin treatment Hetfeld et al., 2008) . Considering the present observation that the NEDD8 pathway modulates MDM2 stability, we asked whether DNA-damaging chemotherapeutic agents regulate the components of the NEDD8 pathway, in particular NEDP1 and Ubc12. Although we did not observe discernible changes in Ubc12 levels in a variety of cell lines following treatment with several chemotherapy drugs (data not shown), NEDP1 proteins levels were consistently induced in several cancer cell lines in response to multiple chemotherapeutic agents, including topoisomerase inhibitors doxorubicin and camptothecin and the radiomimetic neocarzinostatin (Figure 3a , Supplementary Figure 3 and data not shown). Notably, the increase in NEDP1 levels corresponded with elevated p53 and p53-target gene products PUMA and p21, which were consistent with diminishing MDM2 expression (Figure 3a ). In addition, the rise in NEDP1 upon chemotherapy treatment paralleled the appearance of cleaved PARP, a marker of apoptosis (Figure 3a) . In support of a role of NEDP1 in activating p53, ectopic expression of myc-NEDP1 decreased MDM2 levels and correspondingly increased p53 and p53-target PUMA levels in MCF7 cells treated with doxorubicin ( Figure 3b) . Furthermore, doxorubicin treatment of p53À/À SAOS2 osteosarcoma cells increased NEDP1 levels (Supplementary Figure 3c, d , and e) and ectopic expression of p53 in p53À/À H1299 lung adenocarcinoma cells had a negligible effect on NEDP1 expression in contrast to a known p53 target p21 ( Supplementary  Figure 3a) , suggesting that NEDP1 is not a target of p53. In addition, the induction of NEDP1 was similar in AT cells (GM16666) and AT isogenic clonal cells reconstituted with wild-type ATM (GM16667) (Supplementary Figure 3f , g and h). These results suggest that the induction of NEDP1 does not require p53 or ATM and support the notion that the activation of p53 upon chemotherapy treatment is in part due to the induction of NEDP1-mediated destabilization of MDM2.
NEDP1 modulates p53-apoptotic response to chemotherapy
The efficacy of chemotherapy is dependent on a successful execution of p53-mediated apoptosis to override the survival signals acquired by cancer cells. For example, tumors harboring p53 mutations are associated with chemoresistance and predict a considerably worse patient prognosis in comparison with cancers with wildtype p53 (Lowe, 1995) . A prediction then is that forced downregulation of NEDP1, which we show here to be induced in response to DNA-damaging chemotherapies, would promote chemoresistance because of enhanced MDM2-mediated suppression of p53. In support, siRNAmediated knockdown of endogenous NEDP1 promoted MDM2 stabilization, decreased p53 levels and activation and resulted in enhanced chemoresistance of MCF7 cells in response to doxorubicin treatment as measured by reduced levels of cleaved PARP and TUNEL positivity (Figure 4 and Supplementary Figure 4a) . Similar results were observed in HeLa cervical and 786-O renal carcinoma cells possessing wild-type p53 (Supplementary Figure 4b) . Notably, MDM2 itself is a p53 target gene, and as a result MDM2 regulates p53 activity via an autoregulatory feedback. Thus, while the initial MDM2 stabilization upon NEDP1 knockdown leads to increased downregulation of p53, the resulting ultimately attenuates MDM2 levels at later time points (Figure 4a and c) . These results suggest that NEDP1 has a critical role in activating p53 apoptotic response to DNA damage by modulating the levels of MDM2.
An essential response to DNA damage is the uncoupling of MDM2-mediated negative regulation of p53, enabling p53-dependent DNA repair, cell cycle arrest or apoptosis. For example, in response to radiomimetic drug neocarzinostatin, MDM2 becomes phosphorylated by ATM, which abrogates MDM2 binding to the deubiquitylating enzyme HAUSP, resulting in increased ubiquitylation and degradation of MDM2 (Khosravi et al., 1999; Stommel and Wahl, 2004; Meulmeester et al., 2005) . In response to UV, SUMO-specific protease SUSP4 desumoylates MDM2, which enhances MDM2 autoubiquitylation and destabilization (Lee et al., 2006) . Intriguingly, these mechanisms regulating MDM2 destabilization occur early in the DNA damage response ranging from 0.5-2 h (Stommel and Wahl, 2004; Meulmeester et al., 2005; Lee et al., 2006) . We show here that MDM2 destabilization is mediated through increased NEDP1-mediated deneddylation of MDM2 in response to chemotherapy-induced DNA damage (see Figure 4d) . The sustained induction of NEDP1 ranges from 8-72 h post-treatment. Therefore, we appear to have identified a novel mechanism of p53 activation that occurs relatively late in response to DNA damage. p53 is also a target of NEDD8 and p53 neddylation has been shown to inhibit p53 transactivation function. Similar to temporal induction of NEDP1, Xirodimas et al. showed that a decrease in p53 neddylation occurs through an unknown mechanism at later time points (post 8 h) following UV treatment . However, whether NEDP1 directly deneddylates p53 in response to DNA damage is not known. Recent studies have also identified putative NEDD8 substrates involved in DNA repair and replication, including mismatch repair enzymes and replicative helicases (Jones et al., 2008; Xirodimas et al., 2008) . Thus, it is possible that NEDP1 has important functions in the regulation of as yet-to-bedefined components of the DNA damage response.
Identification of biological stimuli that regulate components of the NEDD8 pathway is one of the outstanding questions in the field (Rabut and Peter, 2008) . Here, we show the expression of an NEDD8 isopetidase NEDP1 is induced by DNA-damaging chemotherapeutic agents, and that induction in NEDP1 expression occurs in a variety of tumor cell lines upon treatment with several chemotherapeutic drugs. Our findings suggest that the MDM2-p53 axis is a crucial target of NEDP1 and that NEDP1-mediated activation of p53 through MDM2 destabilization is a common event promoting chemotherapy-induced cell death. Notably, MDM2 is overexpressed in numerous cancers by a variety of gene amplification-independent mechanisms (Levav -Cohen et al., 2005) . Interestingly, Figure 3 Chemotherapy increases NEDP1-mediated p53 activation. (a) MCF7 breast adenocarcinoma cells were treated with 0.1 mM doxorubicin (DOX) (Sigma) (top panel) and U2OS osteosarcoma cells were treated with 300 ng/ml neocarzinostatin (NCS) (Sigma) (bottom panel). Cells were harvested at the indicated time points, lysed and equal amounts of whole cell extract were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (b) MCF7 cells were transfected with empty plasmid (MOCK) or plasmidencoding myc-NEDP1 and treated 48 h post-transfection with 0.1 mM DOX (Sigma). Cells were harvested at the indicated time points, lysed and equal amounts of whole cell extracts were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. The left and right panels are derived from identical exposure of the same immunoblot.
NEDP1 promotes MDM2 destabilization IR Watson et al
NEDP1 is located on chromosome 15q23 and genetic aberrations have been reported in this region in nonsmall cell lung cancers, gliomas, oligodendrigliomas and diffuse-type tenosynovial giant cell tumors (Paunu et al., 2002; Koschny et al., 2006; Huang et al., 2008; Suzuki et al., 2008) . However, it remains an outstanding question as to whether NEDP1 loss has an oncogenic role in mediating MDM2 overexpression in cancer.
NEDP1 promotes MDM2 destabilization IR Watson et al Figure 4 siRNA-mediated downregulation of NEDP1 enhances chemoresistance. (a) MCF7 cells were transfected with siNEDP1-1 (5 0 -GGAUGUACGUGAUAUGUAAdUdU-3 0 and 5 0 -UUACAUAUCACGUACAUCCdUdU-3 0 ) or siCONTROL oligos (siGEN-OME RISC-Free Control siRNA) (Dharmacon, Lafayette, CO, USA) as previously described (Lau et al., 2007) . Cells were treated 48 h post-transfection with 0.1 mM doxorubicin (DOX), harvested at the indicated time points, lysed, equal amounts of whole cell extract resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (b) MCF7 cells were transfected with a second siNEDP1-2 oligo (5 0 CAGAGAAACUGGAGGCUUUdUdU-3 0 and 5 0 -AAAGCCUCCAGUUUCUCUGdUdU-3 0 ). Forty-eight hours posttransfection, cells were treated with 2 mM DOX for 48 h, trypsinized and 5 Â 10 4 cells were mounted on glass slides by cytospin centrifugation. TUNEL assays were performed according to manufacturer's protocol (Promega, Madison, WI, USA) and images were taken by an inverted epifluorescence microscope (Zeiss Axiovert 200). TUNEL-and DAPI-positive cells were counted using Volocity software (Improvision, Coventry, UK) and confirmed by manual counting (left panel). Similar results were observed with additional doses of DOX. Equal amounts of whole cell extracts generated from the remaining cells were resolved by SDS-PAGE and immunoblotted with the indicated antibodies (right panel). (c) MCF7 cells were transfected with siNEDP1-2 or siCONTROL oligos and treated 48 h post-transfection with 0.1 mM DOX. Cells were harvested at the indicated time points and western blot analysis performed (left panel). Cells harvested at 72 h time point were lysed and visualized by immunoblotting with the indicated antibodies (right panel). (d) A model of NEDP1-mediated activation of p53 apoptotic response. Steady-state MDM2 levels are regulated in part by the NEDD8 pathway mediated by the E2-conjugating enzyme Ubc12 and/or other unknown factor(s) and the NEDD8-specific isopeptidase NEDP1. In response to DNA-damage, NEDP1 levels increase to mediate MDM2 deneddylation, resulting in MDM2 destabilization and increased p53 activation to ultimately trigger apoptosis.
